A Phase 1/2 interventional study of A cryopreserved formulation of autologous mPB CD34+ hematopoietic stem and progenitor cells transduced ex vivo with the EFS-ADA lentiviral vector encoding the human ADA enzyme in Adenosine Deaminase Severe Combined Immune Deficiency, sponsored by University of California, Los Angeles. Active, not recruiting at 1 site in United States. Open to participants aged 1 Month and older. Per ClinicalTrials.gov, last updated 2026-08-20.
Sponsored by University of California, Los Angeles · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Severe combined immunodeficiency due to adenosine deaminase deficiency with a site in United States — 2 open to participants now, 4 under way, none of them phase 3. Severe combined immunodeficiency due to adenosine deaminase deficiency · United States.
Among the 16 studies in Severe combined immunodeficiency due to adenosine deaminase deficiency with a site in United States, this one is the only one that started in 2023, is one of 3 in phase 1/2, and was the 16th registered.
29 studies on the registry are indexed under Severe combined immunodeficiency due to adenosine deaminase deficiency; 4 are open to participants now.
Browse Severe combined immunodeficiency due to adenosine deaminase deficiency studies →2 of the 16 studies in Severe combined immunodeficiency due to adenosine deaminase deficiency with a site in United States are open now. Recruiting first, the newest first:
University of California, Los Angeles · Sites in United States, United Kingdom
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States, Canada
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 5 · Phase 3 2
First in 1990; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is above the median of 10 across 13 interventional studies indexed under Severe combined immunodeficiency due to adenosine deaminase deficiency.
Median enrollment 8 across the 9 interventional studies, 76 across the 7 observational. Of the 10 that completed or were terminated, 5 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 16 have an industry lead sponsor. The 9 most frequent:
University of California, Los Angeles is the lead sponsor of 1,172 studies on the registry; 195 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 70 (74%) have results posted.
University of California, Los Angeles has 5 studies filed under Severe combined immunodeficiency due to adenosine deaminase deficiency — fewer than ten, so there is no comparison to draw.
2 of the studies in Severe combined immunodeficiency due to adenosine deaminase deficiency with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
| NCT05432310University of California, Los AngelesGene Therapy for Adenosine Deaminase Severe Combined Immune Deficiency Using Peripheral Blood and EFS ADA Vector | 2027-11-14 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies in Severe combined immunodeficiency due to adenosine deaminase deficiency with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this study is to assess the safety and efficacy of autologous transplantation of hematopoietic stem cells (CD34+ cells) from mobilized peripheral blood (mPB) of ADA-deficient SCID infants and children following human ADA gene transfer by the EFS-ADA lentiviral vector. The level of gene transfer in blood cells and immune function will be measured as endpoints.
The study is open to twenty (20) infants and children diagnosed with ADA-deficient SCID who did not have a medically eligible, human leukocyte antigen (HLA)-identical sibling donor for bone marrow transplantation. The EFS-ADA lentiviral vector with the human ADA complementary DNA (cDNA) will be used to transduce autologous CD34+ cells from Granulocyte Colony Stimulating Factor (G-CSF)/Plerixafor mobilized Peripheral Blood (mPB) of these subjects. The subjects will receive pharmacokinetically-adjusted busulfan reduced intensity conditioning prior to re-infusion of their gene-modified cells. Overall survival at two years is the primary endpoint. During the follow-up phase, the investigators aim to determine whether the cells could engraft and produce mature cells that contain and express the corrected ADA gene in the absence of pegylated adenosine deaminase (PEG-ADA) enzyme replacement therapy (ERT), which will be withheld starting on Day +30 following transplant. Efficacy studies to evaluate the level of immune reconstitution, will be performed in the two years of the study. Patients will be asked to enroll into a long-term follow-up study to reach a total of 15 years follow-up after gene therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All subjects must fulfill the following criteria to be included in the study:
With a diagnosis of ADA-SCID based on:
Evidence of ADA deficiency, defined as:
i. Decreased ADA enzymatic activity in erythrocytes, leukocytes, skin fibroblasts, or in cultured fetal cells to levels consistent with ADA-SCID as determined by the reference laboratory, or ii. Identified mutations in ADA alleles consistent with a severe reduction in ADA activity,
Evidence of ADA-SCID based on either:
i. Family history of a first order relative with ADA deficiency and clinical and laboratory evidence of severe immunologic deficiency, or ii. Evidence of severe immunologic deficiency in subjects prior to the institution of immune restorative therapy, based on
Exclusion Criteria:
Subjects will not be eligible for the study if any of the following criteria is fulfilled:
Hematologic abnormality, defined as:
Pulmonary abnormality, defined as:
Cardiac abnormality, defined as:
Neurologic abnormality, defined as:
Renal abnormality, defined as:
Hepatic/gastrointestinal abnormality, defined as:
Oncologic disease, defined as:
Confirmation of an infectious disease by deoxyribonucleic acid (DNA) polymerase chain reaction (PCR) positive at time of assessment for the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Evaluate safety and efficacy of this autologous gene therapy
Combination Product: A cryopreserved formulation of autologous mPB CD34+ hematopoietic stem and progenitor cells transduced ex vivo with the EFS-ADA lentiviral vector encoding the human ADA enzyme
Autologous transplantation of EFS-ADA lentiviral vector transduced, mPB CD34+ cells by central venous infusion, following reduced intensity conditioning with busulfan
Survival
The primary study outcome will be to determine survival for all subjects 2 years after gene therapy
Time frame: 24 months
Evaluate Safety from clinical adverse events.
Evaluate safety of the treatment by recording clinical adverse events (AE).
Time frame: 24 months
Evaluate Safety from replication competent lentivirus by quantitative polymerase chain reaction (qPCR) assay.
Evaluate safety by recording incidents of replication competent lentivirus by qPCR assay..
Time frame: 24 months
Evaluate Safety from vector-related clonal expansion by non-restrictive Linear Amplification Polymerase Chain Reaction (nrLAM-PCR)
Evaluate safety by recording incidence of vector-related clonal expansion by nrLAM-PCR
Time frame: 24 months
Record event free survival at 24 months
Record Event Free Survival as a definition of "failure" of the therapy. Event-free survival is defined as the proportion of subjects alive with no "event", an "event" being the resumption of PEG-ADA ERT or the need for a rescue allogeneic hematopoietic stem cell transplant (HSCT), or death.
Time frame: 24 months
Determine incidence of Infection over two years after gene therapy
Determine the incidence and severity of infections post-gene therapy (subsequent to hematopoietic reconstitution). Over 2 years, record the incidence of hospitalizations or outpatient-based treatments for systemic bacterial, fungal, or viral infections (including, but not limited to Cytomegalovirus (CMV) infections).
Time frame: 24 months
Neuro-developmental Outcomes by neurodevelopmental testing (subjects 5-7 yeas of age)
Measure neuro-developmental status post-gene therapy. Perform age-appropriate neuro-developmental assessments testing (5- 7 years of age) at baseline and 2 years post-gene therapy - Wechsler Scale of Intelligence
Time frame: 24 months
Neuro-developmental Outcomes by neurodevelopmental testing (subjects 1 year -42 month of age)
Measure neuro-developmental status post-gene therapy. Perform age-appropriate neuro-developmental assessments testing (1 year to 42 months of age) at baseline and 2 years post-gene therapy - : Bayley Scale of Infant Development
Time frame: 24 months
Neuro-developmental Outcomes by Brain Stem Evoked Response (BAER) testing
Measure neuro-developmental status post-gene therapy - Perform Brainstem Auditory Evoked Response test at baseline and at 2 years.
Time frame: 24 months
Cessation of immunoglobulin replacement therapy (IgRT).
Record time post-gene therapy that immunoglobulin replacement therapy (IgRT) is stopped based on defined criteria.
Time frame: 24 months
Exploratory Study Objectives to measure biological correlates of efficacy - Vector Copy Number (VCN) in peripheral blood leukocytes
The Exploratory Study Objectives are to measure biological correlates of efficacy. 1\. Quantify gene marking by vector copy number (VCN) in peripheral blood leukocytes by droplet digital polymerase chain reaction (ddPCR).
Time frame: 24 months
Exploratory Study Objectives to measure biological correlates of efficacy (Vector integrant diversity)
The Exploratory Study Objectives are to measure biological correlates of efficacy. 2\. Quantify clonal diversity of vector integrants by non-restrictive Linear Amplification polymerase chain reaction (nrLAM-PCR). nrLAM-PCR identifies all distinct vector integrants in a cell sample from patients. The presence of \>1,000 unique integration sites in a sample indicates diversity of hematopoietic stem cell of clonal engraftment
Time frame: 24 months
Exploratory Study Objectives to measure biological correlates of efficacy (expressed ADA enzyme in erythrocytes)
The Exploratory Study Objectives are to measure biological correlates of efficacy. 3\. Measure ADA enzyme activity in erythrocytes as an indicator of expression of functional ADA enzyme from the vector.
Time frame: 24 months
Exploratory Study Objectives to measure biological correlates of efficacy Deoxyadenosine nucleotides in erythrocytes)
The Exploratory Study Objectives are to measure biological correlates of efficacy. 4\. Measure total deoxyadenosine nucleotides in erythrocytes.
Time frame: 24 months
Exploratory Study Objectives to measure biological correlates of efficacy (Immune reconstitution - quantify T and B cell)
The Exploratory Study Objectives are to measure biological correlates of efficacy. 5\. Assess immune reconstitution by measuring absolute numbers of T and B cells .
Time frame: 24 months
Exploratory Study Objectives to measure biological correlates of efficacy (Immune reconstitution - measure serum immunoglobulins)
The Exploratory Study Objectives are to measure biological correlates of efficacy. 6\. Assess immune reconstitution by measuring serum immunoglobulin levels
Time frame: 24 months
Exploratory Study Objectives to measure biological correlates of efficacy (Immune reconstitution - response to tetanus vaccine)
The Exploratory Study Objectives are to measure biological correlates of efficacy. 7\. Assess immune reconstitution by measuring response to tetanus vaccine by measuring serum anti-tetanus antibody titers after tetanus vaccination
Time frame: 24 months
Exploratory Study Objectives to measure biological correlates of efficacy Parent report Quality of Life
The Exploratory Study Objectives are to measure biological correlates of efficacy. 8\. Parent-Reported Quality of Life (PedsQL 4.0) at baseline and 2 years.
Time frame: 24 months
Plan to share: No
Started Jan 2023 (actual). Primary completion is estimated for Nov 2027, 58 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Severe combined immunodeficiency due to adenosine deaminase deficiency →
University of California, Los Angeles →